000 02984 a2200361 4500
001 1138198471
005 20250317100353.0
008 250312042016xx 123 eng
020 _a9781138198470
037 _bTaylor & Francis
_cGBP 74.99
_fBB
040 _a01
041 _aeng
072 7 _aPSB
_2thema
072 7 _aPSAK
_2thema
072 7 _aPN
_2thema
072 7 _aMKG
_2thema
072 7 _aPSB
_2bic
072 7 _aPSAK
_2bic
072 7 _aPN
_2bic
072 7 _aMMG
_2bic
072 7 _aMED008000
_2bisac
072 7 _aSCI013000
_2bisac
072 7 _aSCI029000
_2bisac
072 7 _a615.19
_2bisac
100 1 _aFerenc Darvas
245 1 0 _aChemical Genomics and Proteomics
250 _a2
260 _bCRC Press
_c20161014
300 _a244 p
520 _bSince the publication of the pioneering first edition of Chemical Genomics and Proteomics more than seven years ago, the area of chemical genomics has rapidly expanded and diversified to numerous novel methods and subdisciplines, such as chemical glycomics and lipidomics. This second edition has been updated to uniquely reflect this interdisciplinary feature as well as the remarkable developments that have occurred. The new edition also covers innovative applications from cell biology to drug discovery to, more recently, clinical diagnostics and medical practice, which utilize the concepts of chemical genomics. The text provides an overview of the strategies and methodologies of chemical genomics, focusing on emerging technologies and recent applications in the areas of combination chemical genetics, toxicogenomics, drug chemical genomics and proteomics, and orthogonal chemical genetics. It describes the development and application of novel analytical methods used in lipodomics, such as steroidomics. The book also discusses biomarker discovery applications of microarray technologies using DNA, RNA, and protein and glycan arrays. Chapters cover further applications of biomolecular biomarkers for disease diagnosis, in small molecule drug R&D, and during therapeutic use of medicines. These include prognostic, disease specific, response (surrogate), and toxicity biomarkers. In addition, the text explores the principles of contemporary systems biology and genomics in experimental medicine—a new paradigm that demonstrates a network-oriented view and advanced statistical and informatics data management, opening the way toward personalized medicine. Finally, various in silico chemogenomics approaches are addressed for predicting binding of drug candidates to undesirable targets, which would help in designing better clinical candidates with fewer side effects. This new edition benefits a broad range of readers from industrial and academic researchers in drug discovery, medicinal chemistry, and molecular and cell biology to physicians in clinical diagnostics and students in related fields of study.
700 1 _aAndrás Guttman
_4B01
700 1 _aGyörgy Dormán
_4B01
999 _c412
_d412